58.92 +0.52 (0.89%)
Before hours: 9:05AM EDT
|Bid||58.76 x 900|
|Ask||59.00 x 800|
|Day's Range||57.82 - 58.79|
|52 Week Range||39.37 - 65.37|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||63.45|
Joining me on today's call are David Endicott, our Chief Executive Officer; and Tim Stonesifer, our Chief Financial Officer. Accordingly, you should not place undue reliance on any forward-looking statements.
Alcon to Highlight Robust Scientific Program Showcasing Latest Innovations at Virtual ASCRS 2020
Alcon announces European launch of Vivity, the only presbyopia-correcting intraocular lens with X-WAVE technology
Alcon Partners with Actress Cheryl Ladd to Share Her Cataract Journey, Renewed Vision and PanOptimist Story
Swiss-listed eyecare company Alcon <ALCC.S> reported another quarterly loss, specified its profit outlook, boosted projections for the cost of its spinoff from Novartis <NOVN.S> and announced a $300 million restructuring program. The company now expects a core operating margin of 17-17.5% for 2019, compared with 17-18% previously and tweaked its sales goal to 4-5% growth, from 3-5%. Alcon increased its expected separation costs from Novartis to $500 million, from $300 million, due to work on IT systems, among other things.
Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should expect heading into its Q2 2019 earnings release on Thursday.